None listed
Conditions
Brief summary
Kiwifruit has both, viscous fibre and organic acids. Therefore this trial is to study the effect of kiwifruit properties such as organic acids and fibre on blood glucose response. This trial is a pilot study to set up the method to measure gastric emptying as well as to improve our understanding of the possible mechanism involved in glycaemic lowering effect of kiwifruit.
Interventions
A randomised repeated measures design will be used in which each subject receives all diets in a random order. The test foods will be as follows: 1. Weet-Bix™ + sugars in 2 kiwifruit. 2. Weet-Bix™ + 2 whole kiwifruit 3. Weet-Bix™ + 2 whole kiwifruit neutralised 4. Weet-Bix™ + juice of 2 kiwifruit 5. Weet-Bix™ + 2 kiwifruit sugars + kiwifruit organic acids 13C-labelled sodium acetate (100 mg) will be added to the test meal just before consumption (details on the safety of 13C-labelled sodium acetate is stated below). An additional 200 ml of water will be consumed with all diets. On each test day the volunteers will be seated and asked to remain so for the duration of the test. They may continue work, if practical to do so, at the testing location. Once each subject is relaxed and comfortable (approximately 15-20 minutes after arrival), a baseline blood sugar measurement will be taken in duplicate for that day. Each subject will then be given a test food and instructed to consume the whole amount within a ten-minute period. The duration of each testing session be 3 hours and 45 minutes. The participants will be checked off for session attendance. The participants will be under direction observation from the time they come to the clinic till they finish (about 3.45 hours) The duration of the washout between each testing session will be 48 hours
Sponsors
Study design
Eligibility
Inclusion criteria
• Age: Aged between 18 and 40. • Sex: Male or female. • Glucose tolerance: No history of diabetes or evidence of glucose intolerance in a preliminary screening test. • Health: Healthy as gauged by self-assessment and result on the General Health Questionnaire. • Agreement: Subject having given written informed consent to comply with the conditions of the trial.
Exclusion criteria
• Glucose intolerance: Any history of diabetes or evidence of glucose intolerance in a preliminary test (less than or equal to 6.0 mmol/L fasting glucose, International Diabetes Federation recommendation) and HbA1c greater than 40 mmol/mol. • Non-fasting: Having consumed anything apart from water in the twelve hours prior to the test. • Allergic or intolerant kiwifruit or wheat. • Pregnant or breastfeeding. • Long term chronic illnesses requiring treatment, such as cancer and cardiovascular disease. • Gut conditions or drugs effecting gut transit time, such as irritable bowel syndrome, peptic ulcers and laxatives.